Oral formulations will grow to capture 25% share as bioavailability improves and new small-molecule GLP-1s reach the market, appealing to segments seeking greater convenience or avoiding injection-site issues
It suppress appetite, slows gastric emptying, boosts insulin secretion, and reduces glucagon
[16] Reported rates from trials include: Nausea: ~44% Vomiting: ~25% Diarrhea: ~31% Constipation: ~23% Dyspepsia: ~10% These effects reflect slowed gastric motility and are usually mild, but can lead to clinical implications: Dehydration Electrolyte abnormalities ED presentations for poor oral intake
Often, a denial is simply because a doctor forgot to mention your BMI or a secondary condition such as high blood pressure
Variants such as GLP1R rs6923761 and FTO rs9939609 reveal individual differences in peptide pathway activation and weight-loss responsiveness
We adjust slowly, based on your response, appetite changes, and comfort level